MDSCs, which can be characterized by CD11b+ CD33+ expression and divided into several subtypes based on phenotypic, morphologic, and functional heterogeneity, have emerged as major regulators of the immune response in cancer and are the subject of intensive research (42, 43). Here, CD33 is linked to cancer.